Tris(2,4-di-tert-butylphenyl)phosphate


Cat. No.:	HY-136177				
CAS No.:	95906-11-9				
Molecular Formula:	$C_{42}H_{63}O_{4}P$				
Molecular Weight:	662.92				
Target:	Phospholipase				
Pathway:	Metabolic Enzyme/Protease				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

SOLVENT & SOLUBILITY

In Vitro	0, 1	Ethanol : 50 mg/mL (75.42 mM; Need ultrasonic) Acetone : 25 mg/mL (37.71 mM; Need ultrasonic)							
Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg				
		1 mM	1.5085 mL	7.5424 mL	15.0848 mL				
	5 mM	0.3017 mL	1.5085 mL	3.0170 mL					
		10 mM	0.1508 mL	0.7542 mL	1.5085 mL				
	Please refer to the so	lubility information to select the app	propriate solvent.						
In Vivo		1. Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (3.77 mM); Suspended solution; Need ultrasonic							
		2. Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (3.77 mM); Suspended solution; Need ultrasonic							
		Add each solvent one by one: 10% EtOH >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.77 mM); Clear solution							

BIOLOGICAL ACTIVITY				
Description	Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A ₂ (sPLA ₂) through molecular docking ^[1] .			
IC ₅₀ & Target	sPLA ₂ ^[1]			
In Vivo	Tris(2,4-di-tert-butylphenyl)phosphate (TDTBPP; 50 mg/kg and 70 mg/kg) exhibits significant anti-inflammatory activity in			





Product Data Sheet

carrageenan induced paw odema model^[1]. Tris(2,4-di-tert-butylphenyl)phosphate (50 mg/kg and 70 mg/kg) reduces the raw paw odema volume significantly^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Vinuchakkaravarthy T, et al. Active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A(2) through molecular docking. Bioinformation. 2011;7(4):199-206.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA